These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30255471)

  • 1. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.
    Priotti J; Baglioni MV; García A; Rico MJ; Leonardi D; Lamas MC; Menacho Márquez M
    AAPS PharmSciTech; 2018 Nov; 19(8):3734-3741. PubMed ID: 30255471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole.
    Pacheco PA; Rodrigues LNC; Ferreira JFS; Gomes ACP; Veríssimo CJ; Louvandini H; Costa RLD; Katiki LM
    Parasitol Res; 2018 Mar; 117(3):705-712. PubMed ID: 29327323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward novel antiparasitic formulations: Complexes of Albendazole desmotropes and β-cyclodextrin.
    Chattah AK; Pfund LY; Zoppi A; Longhi MR; Garnero C
    Carbohydr Polym; 2017 May; 164():379-385. PubMed ID: 28325339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of albendazole-randomly methylated-β-cyclodextrin inclusion complex and in vivo evaluation of its antihelmitic activity in a murine model of Trichinellosis.
    García A; Leonardi D; Vasconi MD; Hinrichsen LI; Lamas MC
    PLoS One; 2014; 9(11):e113296. PubMed ID: 25406084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the complexation of albendazole with cyclodextrins for the design of new antiparasitic formulations.
    Pradines B; Gallard JF; Iorga BI; Gueutin C; Loiseau PM; Ponchel G; Bouchemal K
    Carbohydr Res; 2014 Oct; 398():50-5. PubMed ID: 25240182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice.
    Ehteda A; Galettis P; Chu SW; Pillai K; Morris DL
    Anticancer Res; 2012 Sep; 32(9):3659-66. PubMed ID: 22993303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of albendazole:β-cyclodextrin citrate in the parenteral stage of Trichinella spiralis infection.
    Codina AV; García A; Leonardi D; Vasconi MD; Di Masso RJ; Lamas MC; Hinrichsen LI
    Int J Biol Macromol; 2015; 77():203-6. PubMed ID: 25790725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (13)C and (15)N solid-state NMR studies on albendazole and cyclodextrin albendazole complexes.
    Ferreira MJ; García A; Leonardi D; Salomon CJ; Lamas MC; Nunes TG
    Carbohydr Polym; 2015 Jun; 123():130-5. PubMed ID: 25843843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of ursolic and oleanolic acids' antitumor activity by complexation with hydrophilic cyclodextrins.
    Oprean C; Mioc M; Csányi E; Ambrus R; Bojin F; Tatu C; Cristea M; Ivan A; Danciu C; Dehelean C; Paunescu V; Soica C
    Biomed Pharmacother; 2016 Oct; 83():1095-1104. PubMed ID: 27551755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising applications in drug delivery systems of a novel β-cyclodextrin derivative obtained by green synthesis.
    García A; Leonardi D; Lamas MC
    Bioorg Med Chem Lett; 2016 Jan; 26(2):602-608. PubMed ID: 26642766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel ternary albendazole-cyclodextrin-polymer systems: dissolution, bioavailability and efficacy against Taenia crassiceps cysts.
    Palomares-Alonso F; González CR; Bernad-Bernad MJ; Montiel MD; Hernández GP; González-Hernández I; Castro-Torres N; Estrada EP; Jung-Cook H
    Acta Trop; 2010 Jan; 113(1):56-60. PubMed ID: 19769931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells.
    Pourgholami MH; Wangoo KT; Morris DL
    Anticancer Res; 2008; 28(5A):2775-9. PubMed ID: 19035309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data.
    Scavone C; Bonagura AC; Fiorentino S; Cimmaruta D; Cenami R; Torella M; Fossati T; Rossi F
    Drugs R D; 2016 Jun; 16(2):129-40. PubMed ID: 26939533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide.
    Lodagekar A; Borkar RM; Thatikonda S; Chavan RB; Naidu VGM; Shastri NR; Srinivas R; Chella N
    Carbohydr Polym; 2019 May; 212():252-259. PubMed ID: 30832855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-beta-cyclodextrin following subcutaneous injection in sheep.
    Wu Z; Tucker IG; Razzak M; Yang L; McSporran K; Medlicott NJ
    Int J Pharm; 2010 Sep; 397(1-2):96-102. PubMed ID: 20621175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.
    Kayser O; Olbrich C; Croft SL; Kiderlen AF
    Parasitol Res; 2003 Jun; 90 Suppl 2():S63-70. PubMed ID: 12937968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes.
    García-Rodriguez JJ; Torrado J; Bolás F
    Parasite; 2001 Jun; 8(2 Suppl):S188-90. PubMed ID: 11484352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue compatibility and pharmacokinetics of three potential subcutaneous injectables for low-pH drug solutions.
    Wu Z; Tucker IG; Razzak M; McSporran K; Medlicott NJ
    J Pharm Pharmacol; 2010 Jul; 62(7):873-82. PubMed ID: 20636875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytotoxic effect of palladium (II) inclusion compounds in beta-cyclodextrin].
    Jaimes N; Salmen S; Colmenares MC; Burgos AE; Tamayo L; Mendoza RV; Cantor A
    Biomedica; 2016 Dec; 36(4):603-611. PubMed ID: 27992987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
    Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
    Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.